Deciphera's TKI drug flops key test in earlier-line GI tumors, sending stock into a tailspin
Despite a very late line approval for its TKI drug last year, Deciphera has had its eyes set on cracking into earlier patients with GI tumors — a possibility investors cheered. But that door has now been slammed shut, and Deciphera’s cheerleaders are fleeing in droves.
Deciphera’s Qinlock (ripretinib) failed a head-to-head matchup against standard-of-care sunitinib in second-line patients with gastrointestinal stromal tumors (GIST) who had previously been treated with TKI inhibitor imatinib, the biotech admitted Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.